
An overview of the c-MET signaling pathway - PMC
c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion. Although ...
Hepatocyte growth factor receptor - Wikipedia
MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. When HGF/SF binds its cognate receptor MET it induces its dimerization through a not yet completely understood mechanism leading to its activation.
Function of the c-Met receptor tyrosine kinase in carcinogenesis …
Feb 19, 2018 · c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor (HGF) is the ligand for this receptor. The binding of HGF to c-Met initiates a series of intracellular signals that mediate embryogenesis and wound healing in normal cells.
Structural basis of the activation of c-MET receptor - Nature
Jul 1, 2021 · C-MET can be activated by either hepatocyte growth factor (HGF), or its natural isoform NK1. Here, we report the cryo-EM structures of c-MET/HGF and c-MET/NK1 complexes in the active state.
c-MET as a potential therapeutic target and biomarker in cancer
The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET ...
The Emerging Role of c-Met in Carcinogenesis and Clinical …
c-MET is a receptor tyrosine kinase receptor (RTK) for the hepatocyte growth factor (HGF). The binding of HGF to c-MET regulates several cellular functions: differentiation, proliferation, epithelial cell motility, angiogenesis, and ...
HGF/c-MET pathway in cancer: from molecular characterization to ...
Jun 18, 2021 · This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers.
Aberrant activation of c-MET can lead to both tumor growth and meta-static progression of cancer cells, making it an important drug target for cancer treatments3,4.
c-Met: structure, functions and potential for therapeutic inhibition
Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis. In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.
C-Met - an overview | ScienceDirect Topics
C-Met is a receptor tyrosine kinase (RTK) that consists of an extracellular alpha chain and a beta subunit. It is activated by its ligand hepatocyte growth factor (HGF), leading to phosphorylation at multiple sites.